Literature DB >> 12067310

Diversity and dynamics of the T-cell response to MBP in DR2+ve individuals.

G Mazza1, M Ponsford, P Lowrey, M J Campbell, J Zajicek, D C Wraith.   

Abstract

It is generally accepted that multiple sclerosis (MS) is mediated by autoreactive T cells and that myelin basic protein (MBP) is one of the target autoantigens. The T-cell response to MBP has been analysed extensively, largely through the use of T-cell lines (TCL) and T-cell clones (TCC), and to date, three immunodominant regions (13-32, 84-103 and 144-163) have been described. However, given that TCL may represent a skewed pattern of peptide reactivity, we have developed a kinetic response assay in which the proliferation of peripheral blood mononuclear cells (PBMC) from MS patients and healthy individuals was measured directly against a panel of peptides spanning the full length of human MBP. Furthermore, PBMC from each subject were tested three times over the course of 18 months. A high proportion of MS patients exhibited a significant response to eight MBP regions (1-24, 30-54, 75-99, 90-114, 105-129, 120-144, 135-159 and 150-170). TCC were subsequently generated from MS subjects and were used to further define the epitope recognized in each case. Overall, normal individuals recognized significantly fewer peptides. In addition, we noted that the T-cell recognition of any one peptide can fluctuate, appearing at one time point, regressing, and subsequently reappearing at a later date. This study provides new insight into the recognition profile and dynamics of myelin-antigen-specific T cells in MS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067310      PMCID: PMC1906251          DOI: 10.1046/j.1365-2249.2002.01831.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.

Authors:  B Bielekova; B Goodwin; N Richert; I Cortese; T Kondo; G Afshar; B Gran; J Eaton; J Antel; J A Frank; H F McFarland; R Martin
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

2.  In vitro cell-mediated immunity of cerebrospinal-fluid lymphocytes to myelin basic protein in primary demyelinating diseases.

Authors:  R P Lisak; B Zweiman
Journal:  N Engl J Med       Date:  1977-10-20       Impact factor: 91.245

3.  Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals.

Authors:  M V Tejada-Simon; J Hong; V M Rivera; J Z Zhang
Journal:  Eur J Immunol       Date:  2001-03       Impact factor: 5.532

4.  Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis.

Authors:  Y C Zang; M M Kozovska; J Hong; S Li; S Mann; J M Killian; V M Rivera; J Z Zhang
Journal:  Eur J Immunol       Date:  1999-05       Impact factor: 5.532

Review 5.  Multiple sclerosis (second of two parts).

Authors:  D E McFarlin; H F McFarland
Journal:  N Engl J Med       Date:  1982-11-11       Impact factor: 91.245

Review 6.  Multiple sclerosis (first of two parts).

Authors:  D E McFarlin; H F McFarland
Journal:  N Engl J Med       Date:  1982-11-04       Impact factor: 91.245

7.  Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species.

Authors:  G E Deibler; R E Martenson; M W Kies
Journal:  Prep Biochem       Date:  1972

8.  Surges of increased T cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with multiple sclerosis than in healthy subjects.

Authors:  M P Pender; P A Csurhes; J M Greer; P D Mowat; R D Henderson; K D Cameron; D M Purdie; P A McCombe; M F Good
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

9.  Differential responses of CD45+ve T-cell subsets to MBP in multiple sclerosis.

Authors:  M Ponsford; G Mazza; J Coad; M J Campbell; J Zajicek; D C Wraith
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

10.  The HLA dictionary 1999: a summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens.

Authors:  G M Schreuder; C K Hurley; S G Marsh; M Lau; M Maiers; C Kollman; H Noreen
Journal:  Hum Immunol       Date:  1999-11       Impact factor: 2.850

View more
  11 in total

Review 1.  Immunopathogenesis of multiple sclerosis: MBP and beyond.

Authors:  E Meinl; R Hohlfeld
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

2.  Differences in susceptibility of MBP charge isomers to digestion by stromelysin-1 (MMP-3) and release of an immunodominant epitope.

Authors:  Cheryl A D'Souza; Mario A Moscarello
Journal:  Neurochem Res       Date:  2006-07-27       Impact factor: 3.996

3.  Reactivity of T cells from women with antibodies to the human platelet antigen (HPA)-1a to peptides encompassing the HPA-1 polymorphism.

Authors:  D J Jackson; M F Murphy; P W Soothill; G F Lucas; C J Elson; B M Kumpel
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

4.  Activated T cell subsets in human type 1 diabetes: evidence for expansion of the DR+ CD30+ subpopulation in new-onset disease.

Authors:  C Baker; L Chang; K A Elsegood; A J Bishop; D H Gannon; P Narendran; N J Leech; C M Dayan
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

5.  Reduction of human anti-tetanus toxoid antibody in hu-PBL-SCID mice by immunodominant peptides of tetanus toxoid.

Authors:  D J Jackson; C J Elson; B M Kumpel
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

6.  Human platelet antigen (HPA)-1a peptides do not reliably suppress anti-HPA-1a responses using a humanized severe combined immunodeficiency (SCID) mouse model.

Authors:  D J Jackson; J L Eastlake; B M Kumpel
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

7.  Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS.

Authors:  Heather B Streeter; Rachel Rigden; Keith F Martin; Neil J Scolding; David C Wraith
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-03-12

8.  ATX-MS-1467 Induces Long-Term Tolerance to Myelin Basic Protein in (DR2 × Ob1)F1 Mice by Induction of IL-10-Secreting iTregs.

Authors:  Adriano Luís Soares De Souza; Stefan Rudin; Rui Chang; Keith Mitchell; Timothy Crandall; Shuning Huang; Ji-Kyung Choi; Shinji L Okitsu; Danielle L Graham; Blake Tomkinson; Tammy Dellovade
Journal:  Neurol Ther       Date:  2018-03-14

Review 9.  An Overview of Peptide-Based Molecules as Potential Drug Candidates for Multiple Sclerosis.

Authors:  Annarita Del Gatto; Michele Saviano; Laura Zaccaro
Journal:  Molecules       Date:  2021-08-28       Impact factor: 4.411

10.  Antigen-specific immunotherapy with apitopes suppresses generation of FVIII inhibitor antibodies in HLA-transgenic mice.

Authors:  Katrien Pletinckx; Kirsty S Nicolson; Heather B Streeter; William J Sanderson; Evelien Schurgers; Lotta Jansson; David C Wraith
Journal:  Blood Adv       Date:  2022-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.